Main Article Content
The article presents data of the modern literature and our studies on the combined use of ursodeoxycholic acid and arginine glutamate in the pathology of the hepatobiliary system. Hepatobiliary diseases today remain a major socio-economic health problem worldwide, occupying a significant place in the structure of general somatic pathology in the clinic of internal medicine. Despite the apparent successes achieved over the past decades in the diagnosis and treatment of diseases of the hepatobiliary system, some issues are still not entirely resolved or there are contradictions about their treatment. It is known that not all hepatotropic drugs meet the requirements for active components that pathogenetically affect the links of pathological processes, which occur in the hepatobiliary tract. It is rather difficult to justify and systematize the treatment of hepatobiliary diseases with such a variety of causes of damage. The principles of modern therapy for most diseases of the hepatobiliary system include the administration of combinations of hepatotropic drugs. One of the most rational combinations of pharmacological agents for these purposes are preparations of ursodeoxycholic acid and arginine glutamate. These pharmacological agents are the drugs with the most substantial evidence base of clinical efficacy, significantly exceeding that of hepatotropic medications of other groups.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Dzyuba AN, Chepelevska LA, Karamzina LA. Current trends in the mortality of the working-age population from diseases of the digestive system. Bulletin of Social Hygiene and Health Protection Organization of Ukraine. 2016;(67):24-29. (in Ukrainian).
Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Medicines (Basel). 2019 Mar 18;6(1). pii: E41. doi: 10.3390/medicines6010041.
Grechanyk M, Grechanyk N, Kuryata A. Lipid metabolism, endothelial function, parameters of elastic properties and inflammation in patients with coronary heart disease combined with hepatic steatosis depending from body mass index. Atherosclerosis. 2018;275:e148 doi: 10.1016/j.atherosclerosis.2018.06.438/.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.
Konerman MA, Walden P, Joseph M, Jackson EA, Lok AS, Rubenfire M. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019 Feb;49(3):296-307. doi: 10.1111/apt.15063.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367.
Filippova OYu. Dynamics of anthropometric and biochemical parameters under the influence of different treatment regimens in patients with non-alcoholic fatty liver disease in combination with obesity and pathology of the biliary tract. Likars'ka sprava. 2017;(1143):54-61. (in Ukrainian).
Nan YM, Fu N, Li WC, et al. An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017. Zhonghua Gan Zang Bing Za Zhi. 2017 Sep 20;25(9):687-694. doi: 10.3760/cma.j.issn.1007-3418.2017.09.008. (in Chinese).
Stepanov YuM, Filippova AYu. Influence body weight and concomitant pathology of the biliary tract on development and progression of lipid abnormalities in patients with nonalcoholic fatty liver disease in combination with obesity. Modern Gastroenterology. 2016;(90):7-15. (in Ukrainian).
Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016 Jan;17(1):68-80. doi: 10.1111/obr.12333.
Stepanov YuM, Filippova AYu. Morphological basis for the assessment of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease associated with obesity and pathology of the biliary tract. Gastroenterologìa. 2017;51(3):196-204. doi: 10.22141/2308-2097.51.3.2017.112636. (in Ukrainian).
Filippova A. Non-alcoholic and alcoholic fatty liver disease in patients suffering from biliary tract pathology and obesity: clinical and functional aspects. Modern Science-Moderni vĕda. 2015;(4):134-149.
Thiele M, Rausch V, Fluhr G, et al. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification. J Hepatol. 2018 May;68(5):1025-1032. doi: 10.1016/j.jhep.2017.12.029.
Lau K, Baumeister SE, Lieb W, et al. The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women. Aliment Pharmacol Ther. 2015 Mar;41(5):467-76. doi: 10.1111/apt.13067.
Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol. 2014 Jul 14;20(26):8393-406. doi: 10.3748/wjg.v20.i26.8393.
Didenko VI, Oshmyanskaya NYu, Klenina IA. Morphological and biochemical evaluation of progression of chronic hepatitis associated with C virus. Gastroenterologìa. 2014;(52):37-41. doi: 10.22141/2308-2097.2.52.2014.81949. (in Russian).
Zavhorodnya NYu, Lukianenko OYu, Yagmur VB, Konenko IS. Gallbladder function and hepatic structural changes in children with nonalcoholic fatty liver disease. Gastroenterologìa. 2016;(60):38-43. doi:10.22141/2308-2097.2.60.2016.74731. (in Ukrainian).
Di Ciaula A, Wang DQ, Portincasa P. Gallbladder and gastric motility in obese newborns, pre-adolescents and adults. J Gastroenterol Hepatol. 2012 Aug;27(8):1298-305. doi: 10.1111/j.1440-1746.2012.07149.x.
Cotton PB, Durkalski V, Romagnuolo J, et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA. 2014 May;311(20):2101-9. doi: 10.1001/jama.2014.5220.
Vinnitskaya EV, Absandze KG, Arkhipova EV, Ivanov AN, Sbikina ES, Sandler YuG. Primary biliary cholangitis and ursodeoxycholic acid: therapy progress and challenges. Doktor Ru. 2019;(158):33-39. doi: 10.31550/1727-2378-2019-158-3-33-39. (in Russian).
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022.
Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2017 Jan;65(1):152-163. doi: 10.1002/hep.28859.
Goroshko OA, Kukes VG, Prokofiev AB, Arkhipov VV, Demchenkova EYu. Clinico-pharmacological aspects of application of antioxidant drugs. International Journal of Applied and Fundamental Research. 2016;(4-5):905-912. (in Russian).
Kim DJ, Yoon S, Ji SC, et al. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep. 2018 Aug 8;8(1):11874. doi: 10.1038/s41598-018-30349-1.
Stepanov YuM, Kosynska SV. Features of ursodeoxycholic acid use in various pathologies of hepatobiliary tract and other organs and systems. Gastroenterologìa. 2014;(54):129-135. doi: 10.22141/2308-2097.4.54.2014.82088. (in Ukrainian).
Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014 Jul;12(7):1090-1100.e2; quiz e61. doi: 10.1016/j.cgh.2013.11.031.
Mueller M, Castro RE, Thorell A, et al. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. Liver Int. 2018 Mar;38(3):523-531. doi: 10.1111/liv.13562.
Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: a meta-analysis (a prisma-compliant study). Medicine (Baltimore). 2016 Oct;95(40):e4949. doi: 10.1097/MD.0000000000004949.
Babak OYa, Fadeyenko HD, Frolov VM, Kruhlova OV. Pathogenetic substantiation of metabolically active agent L-arginine-L-glutamate for treatment of non-alcoholic fatty liver disease combined with non-calculous chronic cholecystitis. Liky Ukrai'ny. 2013;(168):29-33. (in Ukrainian).
Kharchenko NV, Anokhina GA, Kharchenko VV. The hepatic and extra-hepatic effects of the treatment complex with arginine-L and betaine in patients with metabolic syndrome. Modern Gastroenterology. 2015;(83):42-49. (in Ukrainian).
Duka I. The use of ready-made infusion of L-arginine glutamate Argitek in intensive care of emergency conditions. Zdorov’ja Ukrai'ny. Hirurgija, Ortopedija, Travmatologija, Intensyvna terapija. 2019;(35):39. (in Russian).